A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Empagliflozin (Primary)
- Indications Acute heart failure; Chronic heart failure; Decompensated heart failure
- Focus Registrational; Therapeutic Use
- Acronyms EMPULSE
- Sponsors Boehringer Ingelheim
Most Recent Events
- 04 Aug 2023 Results comparing empagliflozin and placebo, stratified by baseline MRA use, published in the European Journal of Heart Failure
- 06 Sep 2022 Results assessing the effect of empagliflozin on eGFR over time and the impact of baseline eGFR on the primary hierarchical outcome of death, worsening heart failure events and quality of life, published in the European Journal of Heart Failure.
- 31 Aug 2022 According to a The Heart Failure Society of America media release, results from this trial will be presented at the The Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), which will take place September 30 - October 3, 2022.